1. Li R, Fu Y, Peng S, Yang F, Ai S, Wang F, Zhang S, Guo H, Qiu X. Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis. Eur J Nucl Med Mol Imaging, 2025 Feb 17. doi: 10.1007/s00259-025-07148-8. （最后通讯作者，1区）
2. Cheng Y, Fan B, Fu Y, Yin H, Lu J, Li D, Li X, Qiu X, Guo H. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram. BMC Urol,2024 Apr 2;24(1):76. (共同通讯作者，3区，IF=2)
3. Qian J, Fu Y, Marra G, Zhang F, Wu X, Li D, Xu L, Qiu X, Gan W, Guo H. Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score-matched analysis. 2024 Mar 20;42(1):170. （共同通讯作者，3区，IF=3）
4. Shi J, Li D, Chen M, Fu Y, Peng S, Zhang Q, Liang J, Lu Q, Lu J, Ai S, Wang F, Qiu X, Guo H. The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study. J Nucl Med, 2024 Mar 4:jnumed.123.266742.（共同通讯作者，1区，IF=9.3）
5. Yang Y(#), Ding M(#), Yin H(#), Chen W, Shen H, Diao W, Yang L, Qin H, Gan W(*), Qiu X(*), Guo H(*). GALNT12 suppresses the bone-specific prostate cancer metastasis by activating BMP pathway via the O-glycosylation of BMPR1A. Int J Biol Sci, 2024 Jan 27;20(4):1297-1313. (共同通讯，2区，IF=9.2)
6. Wang B(#), Fu Y(#), Chen M, Peng S, Marra G, Zhuang J, Zhang S, Guo H(*), Qiu X(*). The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy. Urol Oncol. 2024 Jan 17:S1078-1439(23)00416-7. (最后通讯，3区，IF=2.7)
7. Zhuang J(#), Wang Y(#), Zhang S(#), Fu Y, Huang H, Lyu X, Zhang S, Marra G, Xu L(*), Qiu X(*), Guo H(*). Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. Front Pharmacol, 2023 Jun 26;14:1217303.（共同通讯作者，2区，IF=5.988）
8. Chen M(#), Fu Y(#), Peng S, Zang S, Ai S, Zhuang J, Wang F, Qiu X(*), Guo H(*). The association between [68Ga]PSMA PET/CT response and biochemical progression in patients with high-risk prostate cancer receiving neoadjuvant therapy. J Nucl Med . 2023 Oct;64(10):1550-1555. （共同通讯作者，1区，IF=11.08）
9. Zhang Z(#), Xie T(#), Zhang S(#), Yin H, Zhang X, Zhang S, Chen W, Yu D, Qiu X(*), Zhao W(*), Guo H(*), Zhuang J(*). Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis. Front Pharmacol. 2023 Jan 20;14:1110146. （共同通讯作者，2区，IF=5.988）
10.Yin H(#), Qin H(#), Yang L(#), Chen M, Yang Y, Zhang W, Hao J, Lu Q, Shi J, Zhuang J, Qiu X(*), Guo H(*). circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3. Biomark Res. 2022 Jul 13;10(1):48. （共同通讯作者，2区，IF=8.63）
11.Qiu X(#), Chen M(#), Yin H(#), Zhang Q, Li H, Guo S, Fu Y, Zang S, Ai S, Wang F(*), Guo H(*). Prediction of biochemical recurrence after radical prostatectomy based on preoperative 68Ga-PSMA-11 PET/CT. Front Oncol. 2021 Sep 30;11:745530.（2区，IF=6.24）
12.Yin H(#), Chen M(#), Qiu X(#), Zhang Q, Qiu L, Fu Y, Huang H, Guo S, Ai S, Wang F(*), Guo H(*). Can 68Ga-PSMA-11 PET/CT predict pathological upgrade of prostate cancer from MRI-targeted biopsy to radical prostatectomy? Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3693-3701.（共同第一作者，1区，IF=7.081）
13.Chen M(#), Zhuang J(#), Fu Y(#), Guo S, Zang S, Ai S, Qiu X(*), Wang F(*), Guo H(*). Can 68Ga-PSMA-11 PET/CT predict pathologic response of primary prostate cancer to neoadjuvant androgen deprivation therapy: a pilot study. J Urol. 2021 Apr;205(4):1082-1089. （共同通讯作者，1区，IF=5.925）
14.Qian J(#), Fu Y(#), Wu X, Xu L, Zhang M, Zhang Q, Rosenberg JE, Xu L, Qiu X(*), Guo H(*). Impact of protruded median lobe on perioperative, urinary continence and oncological outcomes of Retzius-sparing robot-assisted radical prostatectomy. Transl Androl Urol. 2021 Feb;10(2):538-547. （共同通讯作者，IF=2.445）
15.Qiu X(#)(*), Li Y(#), Chen M(#), Xu L, Guo S, Marra G, Rosenberg JE, Ma H, Li X, Guo H(*). Retzius-sparing robot-assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, single-blind trial with a 1-year follow-up. BJU Int. 2020 Nov;126(5):633-640. （2区，IF=4.806）
16.Li Y(#), Li W(#), Lu W, Chen M, Gao J, Yang Y, Zhuang J, Li X, Guo H(*), Qiu X(*). Association of Preoperative Urethral Parameters on Magnetic Resonance Imaging and Immediate Recovery of Continence Following Retzius-sparing Robot-Assisted Radical Prostatectomy. Transl Androl Urol ,2020 Apr;9(2):501-509. （共同通讯作者，IF=2.445）
17.Chen M (#), Zhang Q (#), Zhang C (#), Zhou YH, Zhao X, Fu Y, Gao J, Zhang B, Wang F, Qiu X(*), Guo H(*). Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol. 2020 Apr;9(2):382-390. （共同通讯作者，IF=2.445）